Memorial Sloan Kettering Cancer Center | Strategic Alliance Partners

The first and largest national clinical study to evaluate the safety and efficacy of an IGF-1R antibody and an mTOR inhibitor in combination therapy for a range of sarcomas has achieved its primary endpoint of improvement in progression-free survival at 12 weeks in patients with bone and soft-tissue sarcomas.

Alice Y. Ho, MD, discusses postmastectomy radiation therapy for patients with breast cancer who have undergone breastreconstructive surgery.

Patients with advanced renal cell carcinoma could experience a greater quality of life and the same treatment benefit with pazopanib as opposed to sunitinib.

Adding ibrutinib to standard R-CHOP chemotherapy for non-Hodgkin lymphoma resulted in an objective response rate of 100% in the first-line setting.

A dual-target PI3 kinase inhibitor known as IPI-145 demonstrated activity in several types of relapsed and refractory non-Hodgkin lymphoma.

Clifford A. Hudis, MD, ASCO President-Elect and chief of the Breast Cancer Medicine Service and attending physician at Memorial Sloan-Kettering Cancer Center, discusses obesity as a modifiable risk factor for cancer.

An Interview With Jimmie C. Holland, MD, on her research and role in the development of a vital area of cancer care.

Andrew D. Seidman, MD, from Weill Cornell Cancer Center and Memorial Sloan-Kettering Cancer Center, discusses less surgery for patients with breast cancer.

Carol Aghajanian, MD, from the Memorial Sloan-Kettering Cancer Center, discusses the treatment of ovarian cancer with PARP inhibitors.

Renier J. Brentjens, MD, PhD, Leukemia Service, Memorial Sloan-Kettering Cancer Center, discusses the treatment of B-cell malignancies with chimeric antigen receptor(CAR)–modified T cells.

Andrew D. Seidman, MD, from the Memorial Sloan-Kettering Cancer Center, describes his excitement over the genetic advances made in the treatment of patients with cancer.

Susan F. Slovin, MD, PhD, from Memorial Sloan-Kettering Cancer Center, provides an overview of the most promising immunotherapeutic follow-ups to sipuleucel-T in prostate cancer.

Michael J. Morris, MD, medical oncologist, Genitourinary Oncology Service, Memorial Sloan-Kettering Cancer Center, discusses the use of PET imaging for patients with prostate cancer.

Eric J. Sherman, MD, Head and Neck Oncology Service, Memorial Sloan-Kettering Cancer Center, discusses the treatment of anaplastic thyroid cancer with intensity-modulated radiation therapy (IMRT), paclitaxel, and pazopanib.

Novel therapies have heightened the need for clinicians to be well informed on potential skin-related adverse events to help ensure that patients adhere to their regimens and complete treatment.

An interview with José Baselga, MD, PhD, who helped to develop new drugs and combination therapies for the treatment of breast cancer, including the early targeted therapy trastuzumab and the more recent pertuzumab.

José Baselga, MD, PhD, explores the dual inhibition of cell-signaling pathways in breast cancer on several fronts, including new therapies for patients with the HER2-positive subtype and novel ways to target mTOR and the PI3K/Akt/mTOR pathway.

Patients with advanced thyroid cancer who develop resistance to treatment with radioiodine may benefit from the experimental drug selumetinib.

Stuart Lichtman, MD, and William Tew, MD, from Memorial Sloan-Kettering Cancer Center, discuss personalizing treatment for elderly patients with ovarian cancer.

Ghassan K. Abou-Alfa, MD, Gastrointestinal Oncology Service, Memorial Sloan-Kettering Cancer Center, describes a study looking at sorafenib plus doxorubicin compared with doxorubicin alone in patients with advanced hepatocellular carcinoma.

Andrew D. Zelenetz, MD, PhD, from Memorial Sloan-Kettering Cancer Center, describes challenges and emerging treatment approaches for patients with hematologic malignancies.

Ghassan K. Abou-Alfa, MD, from Memorial Sloan-Kettering Cancer Center, discusses the promising results and future investigation of MET inhibition in hepatocellular carcinoma using cabozantinib and tivantinib.

Mark G. Kris, MD, offers insight into NSCLC related topics, including emerging therapeutic targets, the optimal application of TKIs, strategies for patients with poor performance status, maintenance therapies, and the treatment pipeline.

Treating estrogen receptor–positive breast cancer without sparking resistance is a complex endeavor that should involve simultaneously targeting the hormone-signaling and PI3 kinase molecular pathways

Although the association between VEGF and ovarian cancer has been known for quite some time, researchers are still struggling to use drugs that inhibit VEGF and angiogenesis in patients with the disease.

Ana M. Molina, M.D. Genitourinary Oncology Service from Memorial Sloan-Kettering Cancer Center in New York Discusses what Separates MSKCC From Other Top Cancer Centers Worldwide